# nanosynth group now focused on development of leading nanomaterials technology around Pharm2Farm

- Link: https://www.directorstalkinterviews.com/nanosynth-group-now-focused-on-development-of-leading-nanomaterials-technology-around-pharm2farm/4121035913
- Published: 2021-11-30T07:09:12+00:00
- Author: Giles

**nanosynth group plc** (LON:NNN), the AIM quoted company has today presented the
following Strategy Update:

Following the divestment of the non-core activities of Gyrometric and Cloudveil 
and the return of the mask manufacturing equipment to the supplier, the Company 
is now focused on the development of its leading nanomaterials technology around
Pharm2Farm. Mark Duffin was appointed Group CEO in September 2021 and has already
brought new key personnel and resources into the business to strengthen the Company’s
operations and support finance, sales, marketing, HR and quality and management 
functions. The Board is considering relocating its operations in 2022 to a new UK
facility that may include a scalable state-of-the-art production facility for nanomaterials
to ensure that the Company improves its nanoparticle production capacity and capabilities
to deliver at scale.

A review of potential sales markets has been carried out and the exploitation of
the Company’s anti-viral technology remains a key area of focus. In order to reduce
the cost of sale, a UK and overseas network of distributors is being established
to supply masks and related products which incorporate this advanced patented technology.
The Company is witnessing heightened levels of interest in the current market following
recent international and Government guidelines. At the same time the Board is aiming
to review and renegotiate existing contracts, including the Company’s previously
notified contract with VKE where to date 45,000 masks have been delivered from the
initial 250,000 order, to incorporate into this new international distribution network.
In addition to this, the Company plans to target the HVAC market and increase marketing
and social media activities considerably.

A thorough assessment of the Company’s in-house technology and R&D pipeline has 
identified eight market sectors where we can either manufacture products ourselves
or work in partnerships where the partners’ IP, manufacturing capability, routes
to market or other capabilities can be enhanced using our in-house skills or technology.

In addition to these organic growth initiatives within Pharm2Farm, the Group is 
actively looking at growing its technology and market presence in the nanotechnology
and advanced materials space through complimentary acquisitions.

> **Mark Duffin, nanosynth group** **CEO commented:** “I am delighted to report 
> that since joining the Company we have made rapid progress developing and beginning
> to implement our strategy which is designed to establish a firm foundation for
> the business. The Board is committed to generate shareholder value in the short
> to medium term. We will continue to keep stakeholders appraised as we achieve 
> key milestones.”

Share on:
